- Market Capitalization, $K 3,110,289
- Shares Outstanding, K 31,047
- Annual Sales, $ 311,330 K
- Annual Income, $ -9,020 K
- 60-Month Beta 1.78
- Price/Sales 10.17
- Price/Cash Flow N/A
- Price/Book 4.42
|Period||Period Low||Period High||Performance|
| || |
-6.89 (-6.44%)since 08/18/20
| || |
-31.00 (-23.63%)since 06/18/20
| || |
-35.54 (-26.19%)since 09/18/19
The global cannabis beverages market size is set to gain impetus from the increasing popularity of these products owing to their possession of several functional benefits, such as easy availability, ease...
Research Nester published a report titled which delivers a detailed overview of the cannabis beverage market in terms of market segmentation by type, by constituent, by distribution channel, by application,...
GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board...
, /PRNewswire/ -- Cannabis is continuously growing as a popular option for medical treatments due to its beneficial and diverse treatment options. In fact, multiple countries have adopted regulatory...
Psychedelic drug treatments are quickly going mainstream, with new coverage surfacing from 60 Minutes. ...
The psychedelics boom is alive and well thanks in part to a landmark decision on psilocybin mushrooms. ...
The cannabis industry was down for the week due to mixed news. Innovative Industrial Properties (IIPR) posted strong earnings, Aurora Cannabis (ACB) was trending downward, and GW Pharmaceuticals (GWPH)...
Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.
The FDA just approved GW Pharmaceuticals (GWPH) Epidiolex Oral Solution to treat seizures associated with Tuberous Sclerosis Complex. This is the third approval for the drug. On Monday, GW Pharmaceuticals...
The commercial rollout of ABIOMED's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.